Intrasense: Strategic Transition and Ambitions in Artificial Intelligence

Intrasense, a French specialist in medical imaging solutions enhanced with artificial intelligence, announced a 59.3% drop in revenue for the first half of 2026, reaching €646,000. This decline is attributed to delays in the renewal of maintenance contracts and license orders. All of the business was generated within the Myrian® division, which is currently being sold.

This divestment will allow Intrasense to focus on its DUOnco™ artificial intelligence solutions, particularly those designed for oncology. DUOnco™ Pancreas, a solution developed with Guerbet, has obtained certification in Japan. DUOnco™ Unity, in its final stages of development, aims for CE marking by the third quarter of 2026.